

Sequence Alignments

RESULT 3
AAA95442 standard; cDNA; 3280 BP.
ID AAA95442
XX
AC AAA95442;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein coding sequence #1.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
epitope; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
PT CDS 1. 3342
PT /*tag= a
PT /product= "CASB619"
PT

QY	GTCAACCTGAAAGAACATCGGACCCPTTAACCTTGAAATACTACTATCCAGACTCAGACATC	657
PN	WO200058460-A2.	
XX		
XX	05 - OCT - 2000 .	
XX	20 - MAR - 2000 ; 2000WO - EP02478.	
XX	26 - MAR - 1999 ; 99GB - 0007113.	
PR	25 - SEP - 1999 ; 99GB - 0022858.	
XX		
(SMIK) SMITHKLINE BEECHAM BIOLOGICALS.		
XX		
XX	Bruck CEM , Cassart J , Coche T , Vinals De Bassols YC;	
XX		
XX	WPL: 2000-664923/64 .	
DR	P-FSDB; AAB26179.	
XX		
XX	Novel CASB619 polypeptides useful for diagnosis, and as vaccines for prophylactic and therapeutic treatment of, cancers, particularly ovarian and colon carcinoma, and autoimmune diseases -	
XX		
PS	Claim 13; Page 53-54; 68pp; English.	
XX		
CC	The present sequence comprises the human CASB619 coding sequence. This protein is thought to be specifically or over-expressed in tumour cells, and so can be used as a target for antigen-specific immune responses which can cause destruction of the tumour cell. In addition, the protein can be used in cancer diagnosis, in the treatment of autoimmune diseases and in vaccines against cancer and autoimmune disease. The invention provides a number of epitopes derived from the protein which can be used as immunogens.	
CC		
CC	Sequence 3280 BP; 810 A; 930 C; 797 G; 743 T; 0 other;	
CC		
SQ	Query Match 97.8%; Score 3259; 6; DB 21; Length 3280;	
	Best Local Similarity 99.8%; Pred. No. 0;	
	Mismatches 3273; Conservative 0; Mismatches 4; Indels 1; gaps 1;	
QY	ATGGCTGAGCCCTGGCACAGGCCACCATTCTCGCCAGAGTCTAGGGAAAGAACTGAGAGG	117
Db	1 ATGGCTGAGCCCTGGCACAGGCCACCATTCTCGCCAGAGTCTAGGGAAAGAACTGAGAGG	60
QY	CGATATCCCCGGCTGTGGGGCTGTCTCTGGCTGGACCCCTTCAGGTGAGCCAG	177
Db	1 CGATATCCCCGGCTGTGGCTGGACCCCTTCAGGTGAGCCAG	120
QY	GGACGGGGACGGGGTTCCAGGTGGAGGAGCTTGATGAAAGACTGAGCTGGAC	180
Db	1 GGAAAGGGACGGGGTTCCAGGTGGAGGAGCTTGATGAAAGACTGAGCTGGAC	297
QY	TGTGACAGGGACGGGGTTCCAGGTGGAGGAGCTTGATGAAAGACTGAGCTGGAC	237
Db	1 TGTGACAGGGACGGGGTTCCAGGTGGAGGAGCTTGATGAAAGACTGAGCTGGAC	240
QY	AGCTGGCTGAGCCGGTCAAGGGACGGGTCAACCCGGGGAGTT	357
Db	1 AGCTGGCTGAGCCGGTCAAGGGACGGGTCAACCCGGGGAGTT	300
QY	CTGGATATGGAGGACGGTCAAGGTGGATGAGTGGATGAGCTGGCTGAGCCAG	417
Db	1 CTGGATATGGAGGACGGTCAAGGTGGATGAGTGGATGAGCTGGCTGAGCCAG	360
QY	GGCATTCGGTGTGGATGAGTGGATGAGCTGGCTGAGCCAG	477
Db	1 GGATTCGGTGTGGATGAGTGGATGAGCTGGCTGAGCCAG	420
QY	ATGGAGTGGATGAGCTGGCTGAGCTGGCTGAGCCAG	537
Db	1 ATGGAGTGGATGAGCTGGCTGAGCTGGCTGAGCCAG	480
QY	CCCCGGGGGACTACATGCCCTCAACGGACGAATGATGCC	597
Db	1 CCCCGGGGGACTACATGCCCTCAACGGACGAATGATGCC	540

Qy	1678	ATGGAGGAAACACTACCAGGAGCTTCACTGGGCCCTCCAGAGGACACTTTCATGAG	1737		Db	2701	ATCCTCAAACCATGATTTCTGGTGAAGTGGCACCTGTACTGC	2760
Db	1621	ATGGAGGAAACACTACCAGGAGCTTCACTGGGCCCTCCAGAGGACACTTTCATGAG	1680		Qy	2818	ATCCTGCTCACCGTCTTGACCTGCTACTTTGGAAAAGATAAAACTAGATACAAG	2877
Qy	1738	GCAAGCAGAAGTACACCAATTGACGTTGCAAGATCTACTCATCATGTCACCATGTT	1797		Db	2761	ATCCTGCTCACCGTCTTGACCTGCTACTTTGGAAAAGATAAAACTAGATACAAG	2820
Db	1681	GCAAGCAGAAGTACACCAATTGACGTTGCAAGATCTACTCATCATGTCACCATGTT	1740		Qy	2878	TACTCCAAGCTGTGATGATGTCACTCTCAAGGACTGTAACCTGCCAGGAGTCACGC	2937
Qy	1798	ATGAATGGCTGGCTCCACTGCGCTTCAGTGGCCCTGCTGATGTGGCTCC	1857		Db	2880	TACTCCAAGCTGTGATGATGTCACTCTCAAGGACTGTAACCTGCCAGGAGTCACGC	2880
Db	1741	ATGAATGGCTGGCTCCACTGCGCTTCAGTGGCCCTGCTGATGTGGCTCC	1800		Qy	2938	TGCGCCATCATGGAAAGGAGATGAGGAGACTTACCTTACCCAGAAAGA-TCA	2996
Qy	1858	TCTGTGACCTCTGTGCTGGTTACTATATTGACCGAGATTAGCAACTGCCACTCC	1917		Db	2881	TGCGCCATCATGGAAAGGAGATGAGGAGACTTACCTTACCCAGAAAGA-TCA	2940
Db	1801	TCTGTGACCTCTGTGCTGGTTACTATATTGACCGAGATTAGCAACTGCCACTCC	1860		Qy	2997	CTCTTGGGAAAGATCAAATTCATTAACTCCAAAGGAGACTCTGTATGGATTGAC	3056
Qy	1918	TGCCCCCTAACAAATTGTAAGGCCCACAGCCATTGGTGCTGAGCTGTGCCC	1977		Db	2941	CTCTTGGGAAAGATCAAATTCATTAACTCCAAAGGAGACTCTGTATGGATTGAC	3000
Db	1861	TGCCCCCTAACAAATTGTAAGGCCCACAGCCATTGGTGCTGAGCTGTGCCC	1920		Qy	3057	CGCTGAAGAACATCTCAGGAGCCAGACATGGACTGTGAGGGACTGCTGCTCA	3116
Qy	1978	TCTGTGAGGACCAAGAACAAAGTCAACTCTGTGTCATAATGATTGACCTTC	2037		Db	3001	CGCTGAAGAACATCTCAGGAGCCAGACATGGACTGTGAGGGACTGCTGCTCA	3060
Db	1921	TGGTGTCAAGGACCAAGAACAAAGTCAACTCTGTGTCATAATGATTGACCTTC	1980		Qy	3117	CCTGCCCTCCTCACCTGATGACCCATTGGGCTGCGGATTTGGGNGCCAGCATC	3176
Qy	2038	TCAAGCAACACTCAACAGGACTTCAACTACAACCTCTCGGTTGGCAAAACACCGTC	2097		Db	3061	CCTGCCCTCCTCACCTGATGACCCATTGGGCTGCGGATTTGGGNGCCAGCATC	3120
Db	1981	TCAAGCAACACTCAACAGGACTTCAACTACAACCTCTCGGTTGGCAAAACACCGTC	2040		Qy	3177	CTGCAACACCCACTGTGGAATATCTCTCATGTCGCTTATCAGATGTTTCAG	3236
Qy	2098	ACTCTTGCTGGAGGGCAAGGPTCACTTCAAAAGGGTGAATACTCATCTTAC	2157		Db	3121	CTGCAACACCCACTGTGGAATATCTCTCATGTCGCTTATCAGATGTTTCAG	3180
Db	2041	ACTCTTGCTGGAGGGCAAGGCTCAAGCTTCAACTACAACCTCTCGGTTGGCAAAACACCGTC	2100		Qy	3237	ATCTTTTTTATAGATGACCCAAACCTCCCTTCGCTTATGCTTACACTGCAAAATA	3296
Qy	2158	CTCAGTCCTGTGAAACACAGGTTAGGAAATGCTGTGACCGACAATGTCAG	2217		Db	3181	ATCTTTTTTATAGATGACCCAAACCTCCCTTCGCTTATGCTTACACTGCAAAATA	3240
Db	2101	CTCAGTCCTGTGAAACACAGGTTAGGAAATGCTGTGACCGACAATGTCAG	2160		Qy	3297	CCACACATTGTTGTTAAATTAAAAAAATAAAAAAATAAAAAAATAAAAAA	3334
Qy	2218	CTCCGGATTCCTCAGGGTAGCAGGGTACAGGTTGACCGAAATGCTGTGAC	2277		Db	3241	CCACACATTGTTGTTAAATTAAAAAAATAAAAAAATAAAAAAATAAAAAA	3278
Db	2161	CTCCGGATTCCTCAGGGTAGCAGGGTACAGGTTGACCGAAATGCTGTGAC	2220					
Qy	2278	GCAGTCATATCCCCAGAGGGACAGGCTAACAGGAGATGACCTGGTGAATCAC	2337					
Db	2221	GCAGTCATATCCCCAGAGGGACAGGCTAACAGGAGATGACCTGGTGAATCAC	2280					
Qy	2318	AGCCTGCTGATGACTATTGGGTGACAACAGATAAGTACCTGGTGAATCAC	2397					
Db	2221	AGCCTGCTGATGACTATTGGGTGACAACAGATAAGTACCTGGTGAATCAC	2340					
Qy	2398	CCAGCTGACTTCCACCTGGTCTGGGAGATAACCGGAGCTTCTGGTGAATCAC	2457					
Db	2341	CCAGCTGACTTCCACCTGGTCTGGGAGATAACCGGAGCTTCTGGTGAATCAC	2400					
Qy	2438	AGTCCACAAAAACTGTCTGGAAATGGGTGACAACAGATAAGTACCTGGTGA	2577					
Db	2461	AGTCCACAAAAACTGTCTGGAAATGGGTGACAACAGATAAGTACCTGGTGA	2520					
Qy	2578	TGTGATGGCTGCAACTTCACCTCCTGCTGAGTCTGCTGCTGAGTCAGTGG	2517					
Db	2521	TGTGATGGCTGCAACTTCACCTCCTGCTGAGTCTGCTGAGTCAGTGG	2580					
Qy	2638	GTGGTGGAGAACCCAAAGCTTACCTGCTGAGTCTGCTGAGTCAGTGG	2697					
Db	2581	GTGGTGGAGAACCCAAAGCTTACCTGCTGAGTCTGCTGAGTCAGTGG	2640					
Qy	2698	GTGGTGGAGAACCCAAAGCTTACCTGCTGAGTCTGCTGAGTCAGTGG	2757					
Db	2641	GTGGTGGAGAACCCAAAGCTTACCTGCTGAGTCTGCTGAGTCAGTGG	2700					
Qy	2758	ATCTGCAARACCATAGATTTCTGGCTGAAAGTGGCARCTCTGAGGGCACCTGTACTGCC	2817					

RESULT 2

AAB26179	Human CASB619 standard; Protein; 1013 AA.	Qy 301 SNKGETSCHQCDPDKYSEKGSSCNVRPACTDKDYFYTHTACDANGETOLMYKWA Db 301 SNKGETSCHQCDPDKYSEKGSSCNVRPACTDKDYFYTHTACDANGETOLMYKWA AC 12-FEB-2001 (first entry)	Qy 301 SNKGETSCHQCDPDKYSEKGSSCNVRPACTDKDYFYTHTACDANGETOLMYKWA Db 301 SNKGETSCHQCDPDKYSEKGSSCNVRPACTDKDYFYTHTACDANGETOLMYKWA DT Human CASB619 protein #1.	Qy 361 SEDLEGAVKLPSASGYKTHCPCNPGEFFKTNSTCOPCPYGSYSNGSDCTRCPAGEPAVG Db 361 SEDLEGAVKLPSASGYKTHCPCNPGEFFKTNSTCOPCPYGSYSNGSDCTRCPAGEPAVG XX Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
DE Human CASB619 protein #1.	KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine; epitope.	Qy 421 FEYKWNTLPLTNMETYVLISGINFEYKGMIGWEYAGDHITYTAAGASDNDENMILTVPGFR Db 421 FEYKWNTLPLTNMETYVLISGINFEYKGMIGWEYAGDHITYTAAGASDNDENMILTVPGFR OS Homo sapiens.	Qy 421 FEYKWNTLPLTNMETYVLISGINFEYKGMIGWEYAGDHITYTAAGASDNDENMILTVPGFR Db 421 FEYKWNTLPLTNMETYVLISGINFEYKGMIGWEYAGDHITYTAAGASDNDENMILTVPGFR XX XX	Qy 421 FEYKWNTLPLTNMETYVLISGINFEYKGMIGWEYAGDHITYTAAGASDNDENMILTVPGFR Db 421 FEYKWNTLPLTNMETYVLISGINFEYKGMIGWEYAGDHITYTAAGASDNDENMILTVPGFR PN WO200508460-A2.
PR 05-OCT-2000.	PD 05-OCT-2000.	Qy 481 PPOSMADTENKEVARITFVFTPLSYNCELYFMVGNSRNTPVETWKGSKGSQSYTYI Db 481 PPOSMADTENKEVARITFVFTPLSYNCELYFMVGNSRNTPVETWKGSKGSQSYTYI XX 20-MAR-2000; 2000WO-EP02478.	Qy 481 PPOSMADTENKEVARITFVFTPLSYNCELYFMVGNSRNTPVETWKGSKGSQSYTYI Db 481 PPOSMADTENKEVARITFVFTPLSYNCELYFMVGNSRNTPVETWKGSKGSQSYTYI XX 26-MAR-1999; 99GB-0007113.	Qy 481 PPOSMADTENKEVARITFVFTPLSYNCELYFMVGNSRNTPVETWKGSKGSQSYTYI Db 481 PPOSMADTENKEVARITFVFTPLSYNCELYFMVGNSRNTPVETWKGSKGSQSYTYI PR 25-SEP-1999; 99GB-0022858.
XX XX	PA (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.	Qy 541 IEENTTTSFATFQRTTFHEASRKYTNDVAKIYSINTNTVANGVASYCRPCALESDVGS Db 541 IEENTTTSFATFQRTTFHEASRKYTNDVAKIYSINTNTVANGVASYCRPCALESDVGS XX XX	Qy 541 IEENTTTSFATFQRTTFHEASRKYTNDVAKIYSINTNTVANGVASYCRPCALESDVGS Db 541 IEENTTTSFATFQRTTFHEASRKYTNDVAKIYSINTNTVANGVASYCRPCALESDVGS PR PR	Qy 541 IEENTTTSFATFQRTTFHEASRKYTNDVAKIYSINTNTVANGVASYCRPCALESDVGS Db 541 IEENTTTSFATFQRTTFHEASRKYTNDVAKIYSINTNTVANGVASYCRPCALESDVGS XX XX
DR N-PSDB; AIA85442.	PB 2000-664923/64.	Qy 601 SCTSPAGYYIDRDGTCHSCPPNTILKAHOPYGYACVPGPGRNNKTHSLCNDCTF Db 601 SCTSPAGYYIDRDGTCHSCPPNTILKAHOPYGYACVPGPGRNNKTHSLCNDCTF PR P	Qy 601 SCTSPAGYYIDRDGTCHSCPPNTILKAHOPYGYACVPGPGRNNKTHSLCNDCTF Db 601 SCTSPAGYYIDRDGTCHSCPPNTILKAHOPYGYACVPGPGRNNKTHSLCNDCTF XX XX	Qy 601 SCTSPAGYYIDRDGTCHSCPPNTILKAHOPYGYACVPGPGRNNKTHSLCNDCTF Db 601 SCTSPAGYYIDRDGTCHSCPPNTILKAHOPYGYACVPGPGRNNKTHSLCNDCTF PR PR
DRR	PB 2000-664923/64.	Qy 661 SRNPTTRTENYNFSALANTVLAGGSPSETSKGLKWHFPLTSLCGQNQREMSVCTDNVTD Db 661 SRNPTTRTENYNFSALANTVLAGGSPSETSKGLKWHFPLTSLCGQNQREMSVCTDNVTD XX XX	Qy 661 SRNPTTRTENYNFSALANTVLAGGSPSETSKGLKWHFPLTSLCGQNQREMSVCTDNVTD Db 661 SRNPTTRTENYNFSALANTVLAGGSPSETSKGLKWHFPLTSLCGQNQREMSVCTDNVTD PR PR	Qy 661 SRNPTTRTENYNFSALANTVLAGGSPSETSKGLKWHFPLTSLCGQNQREMSVCTDNVTD Db 661 SRNPTTRTENYNFSALANTVLAGGSPSETSKGLKWHFPLTSLCGQNQREMSVCTDNVTD XX XX
XX XX	PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for prophylactic and therapeutic treatment of, cancers, particularly ovarian and colon carcinoma, and autoimmune diseases -	Qy 721 LRIPGESEGSFSKSITAYQCQAVIIPPEVTGKAVGSSQVSLADRLLIGTTDMTLDGITS Db 721 LRIPGESEGSFSKSITAYQCQAVIIPPEVTGKAVGSSQVSLADRLLIGTTDMTLDGITS PR PR	Qy 721 LRIPGESEGSFSKSITAYQCQAVIIPPEVTGKAVGSSQVSLADRLLIGTTDMTLDGITS Db 721 LRIPGESEGSFSKSITAYQCQAVIIPPEVTGKAVGSSQVSLADRLLIGTTDMTLDGITS XX XX	Qy 721 LRIPGESEGSFSKSITAYQCQAVIIPPEVTGKAVGSSQVSLADRLLIGTTDMTLDGITS Db 721 LRIPGESEGSFSKSITAYQCQAVIIPPEVTGKAVGSSQVSLADRLLIGTTDMTLDGITS PR PR
PS DR	Claim 4: Page 54-56; 68pp; English.	Qy 781 PAELFHIELSLGIPDVIFYRNSNDVTQSSSGRSTTIRVRCSPQKTVPSQLLPGTCSPGT Db 781 PAELFHIELSLGIPDVIFYRNSNDVTQSSSGRSTTIRVRCSPQKTVPSQLLPGTCSPGT XX XX	Qy 781 PAELFHIELSLGIPDVIFYRNSNDVTQSSSGRSTTIRVRCSPQKTVPSQLLPGTCSPGT Db 781 PAELFHIELSLGIPDVIFYRNSNDVTQSSSGRSTTIRVRCSPQKTVPSQLLPGTCSPGT CC CC	Qy 781 PAELFHIELSLGIPDVIFYRNSNDVTQSSSGRSTTIRVRCSPQKTVPSQLLPGTCSPGT Db 781 PAELFHIELSLGIPDVIFYRNSNDVTQSSSGRSTTIRVRCSPQKTVPSQLLPGTCSPGT CC CC
DRR	PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for prophylactic and therapeutic treatment of, cancers, particularly ovarian and colon carcinoma, and autoimmune diseases -	Qy 840 CDGCNFHFLWESAAACPLCSYADYHAIVSSCYAGIQKTTYWREPKLCGGSLPPEQRT Db 840 CDGCNFHFLWESAAACPLCSYADYHAIVSSCYAGIQKTTYWREPKLCGGSLPPEQRT XX XX	Qy 840 CDGCNFHFLWESAAACPLCSYADYHAIVSSCYAGIQKTTYWREPKLCGGSLPPEQRT Db 840 CDGCNFHFLWESAAACPLCSYADYHAIVSSCYAGIQKTTYWREPKLCGGSLPPEQRT PR PR	Qy 840 CDGCNFHFLWESAAACPLCSYADYHAIVSSCYAGIQKTTYWREPKLCGGSLPPEQRT Db 840 CDGCNFHFLWESAAACPLCSYADYHAIVSSCYAGIQKTTYWREPKLCGGSLPPEQRT XX XX
XX XX	PT invention provides a number of epitopes derived from the protein which can be used as immunogens.	Qy 900 ICKTIDFWLKYGISAGCTTAILLTWTCTYFWKKKNQDLEYKYSKLYMNATLKDCLEAADS Db 900 ICKTIDFWLKYGISAGCTTAILLTWTCTYFWKKKNQDLEYKYSKLYMNATLKDCLEAADS PR PR	Qy 900 ICKTIDFWLKYGISAGCTTAILLTWTCTYFWKKKNQDLEYKYSKLYMNATLKDCLEAADS Db 900 ICKTIDFWLKYGISAGCTTAILLTWTCTYFWKKKNQDLEYKYSKLYMNATLKDCLEAADS XX XX	Qy 900 ICKTIDFWLKYGISAGCTTAILLTWTCTYFWKKKNQDLEYKYSKLYMNATLKDCLEAADS Db 900 ICKTIDFWLKYGISAGCTTAILLTWTCTYFWKKKNQDLEYKYSKLYMNATLKDCLEAADS PR PR
PS SQ	Sequence 1013 AA:	Qy 961 CAIMEGEDYEDDLIFTSKNSLGR 984	Qy 961 CAIMEGEDYEDDLIFTSKNSLGR 984	Qy 961 CAIMEGEDYEDDLIFTSKNSLGR 984
XX XX	Query Match 97.6%; Score 5376; DB 21; Length 1013; Best Local Similarity 99.4%; Pred. No. 0; Matches 978; Conservative 1; Mismatches 5; Indels 0; Gaps 0;	Db 961 CAIMEGEDYEDDLIFTSKNSLGR 984	Db 961 CAIMEGEDYEDDLIFTSKNSLGR 984	Db 961 CAIMEGEDYEDDLIFTSKNSLGR 984

101	1	US-08-318-947A-19
102	6	US-08-295-303A-19
102	6	Sequence 19, App
103	6	Sequence 22, App
103	6	Sequence 176, App
104	6	Sequence 09-071-035-176
104	6	Sequence 5333, App
105	6	US-09-134-001C-5333
105	6	Sequence 5038, App
106	6	US-09-134-001C-5038
106	6	Sequence 174, App
107	6	US-09-071-035-174
107	6	Sequence 15, App
108	6	US-09-215-252-15
108	6	Sequence 27, App
109	6	US-08-118-270-27
109	6	Sequence 27, App
110	6	PCT-US93-08528-27
110	6	Sequence 32, App
111	6	US-09-058-051A-32
111	6	Sequence 29, App
112	6	US-08-793-410-29
112	6	Sequence 30, App
113	6	US-08-193-410-30
113	6	Sequence 1, App
114	6	US-07-867-105B-1
114	6	Sequence , App
115	6	US-08-793-410-6
115	6	Sequence 6, App
116	6	US-08-793-410-6
116	6	Sequence 7, App
117	6	US-08-793-410-7
117	6	Sequence 2, App
118	6	US-09-184-856-2
118	6	Sequence 4, App
119	6	US-09-085-205-4
119	6	Sequence 48, App
120	6	US-08-853-652A-48
120	6	Sequence 4, App
121	6	US-08-356-180-4
121	6	Sequence 13, App
122	6	US-09-006-353A-13
122	6	Sequence 13, App
123	6	US-09-573-986-13
123	6	Sequence 1, App
124	6	US-09-157-160-3
124	6	Sequence 1, App
125	6	US-09-587-436-1
125	6	Sequence 1, App
126	6	US-08-927-1165A-1
126	6	Sequence 1, App
127	6	US-09-576-160B-1
127	6	Sequence 2, App
128	6	US-09-229-418-2
128	6	Sequence 2, App
129	6	US-08-932-761A-2
129	6	Sequence 2, App
130	6	US-09-307-912-2
130	6	Sequence 2, App
131	6	PCT-US95-044664-2
131	6	Sequence 2, App
132	6	US-09-068-4569-2
132	6	Sequence 2, App
133	6	US-09-288-143-211
133	6	Sequence 2, App
134	6	US-09-134-001C-4760
134	6	Sequence 26, App
135	6	US-09-145-751-36
135	6	Sequence 36, App
136	6	US-08-979-424-3
136	6	Sequence 3, App
137	6	US-08-928-383B-2
137	6	Sequence 23, App
138	6	US-08-928-383B-23
138	6	Sequence 24, App
139	6	US-08-928-383B-24
139	6	Sequence 25, App
140	6	US-08-928-383B-26
140	6	Sequence 2, App
141	6	US-08-927-2496-2
141	6	Sequence 50, App
142	6	US-09-554-612C-50
142	6	Sequence 2, App
143	6	US-08-416-756A-2
143	6	Sequence 2, App
144	6	US-08-886-965-2
144	6	Sequence 13, App
145	6	US-08-915-552-13
145	6	Sequence 375, App
146	6	US-08-637-755A-375
146	6	Sequence 375, App
147	6	US-08-871-355A-375
147	6	Sequence 375, App
148	6	US-09-201-945-375
148	6	Sequence 375, App
149	6	US-08-605-106-13
149	6	Sequence 13, App

ALIGNMENTS

RESULT 1
US-0190-029A-10
; Sequence 10, Application US/08190029A
; Patent No. 5,736363
; GENERAL INFORMATION:
; APPLICANT: EDWARDS, Richard Mark
; APPLICANT: BAWDEN, Lindsey
; TITLE OF INVENTION: TGP-II ANALOGUE
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ALLEGRETTI & WITCOFF
; STREET: 10 S. WACKER DRIVE, SUITE
; CITY: CHICAGO
; STATE: ILLINOIS
; COUNTRY: U.S.A.
; 50506
; FILED FORM: 50506
; PRIORITY DATE: 08/19/00
; APP'D DATE: 08/19/00
; BY: D.A.
; 50506

RESULT 1
AAF28030
ID AAF28030 standard; DNA; 3334 BP.
XX
AC AAF28030;
XX
XX 08-MAY-2001 (first entry)
XX
DE Human TR13 receptor coding sequence SEQ ID NO: 39.
XX
KW Human; tumour necrosis factor Receptor; TR13; TR14; infection;
KW cancer; autoimmune disease; allergy; inflammatory disease;
KW graft rejection; apoptosis; cardiovascular disease; aneurysm; ds.
XX
OS Homo sapiens.
XX
PN WO200105814-A1.
XX
PD 25-JAN-2001.
XX
PF 14-JUL-2000; 2000WO-US19343.
XX
PR 16-JUL-1999; 99US-0144087.
PR 18-AUG-1999; 99US-0149450.
PR 20-AUG-1999; 99US-0149712.
PR 10-SEP-1999; 99US-0153089.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PT Ruben SM, Ni J, Young PE;
XX
DR WPI; 2001-112682/12.

XX Nucleic acids encoding 2 human tumor necrosis factor receptor
PT polypeptides ((TR13) and (TR14)), useful for the prevention, diagnosis
PT and treatment of, e.g. cancers, acquired immune deficiency syndrome and
PT hypohidrotic ectodermal dysplasia -
XX
PS Claim 4; Page 394-398; 418pp; English.
XX
The present invention provides the protein and coding sequences of the
CC human tumour necrosis factor receptors TR13 and TR14. These sequences are
CC useful in the diagnosis and treatment of many diseases, including cancer,
CC autoimmune diseases, cardiovascular disorders, allergies,
CC neurodegenerative diseases, graft rejection, inflammation, aneurysms and
CC infections.

XX Sequence 3334 BP; 820 A; 952 C; 811 G; 751 T; 0 other;	QY 781 CTCTATTGGAGAACCAACGCCCTTCAGTGGACCAAAAGTACCCAAACCTGCTGGTGGT 840
SQ Query Match 100.0%; Score 3334; DB 22; Length 3334; Best Local Similarity 100.0%; Pred. No. 0; Matches 3334; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	Db 781 CTCTATTGGAGAACCAACGCCCTTCAGTGGACCAAAAGTACCCAAACCTGCTGGTGGT 840
QY 1 GGAGAACCGAGCCGGCAGCACCTGAGCCTCACAGGAAACGCCTATG 60	QY 841 AGAACATGGCCAACGGTGGCTACACTTCAGATGGCTCCCTGCAAACCTGCGGC 900
Db 1 GGAGAACCGAGCCGGCAGCACCTGAGCCTCACAGGAAACGCCTATG 60	Db 841 AGAACATGGCCAACGGTGGCTACACTTCAGATGGCTCCCTGCAAACCTGCGGC 900
QY 61 GCTGAGCTGGCACGCCAACCATCTCCCGCAGAGTCAGGGAAACTGAGGGC 120	QY 901 ACSTPAGAGACAGCAGGGCTTCAGTTCTGCAAACACTTCTATGTTATATCA 960
Db 61 GCTGAGCTGGCACGCCAACCATCTCCCGCAGAGTCAGGGAAACTGAGGGC 120	Db 901 ACGPATGCGACAGCAGGGCTTCAGTTCTGCAAACACTTCTATGTTATATCA 960
QY 121 ATACCCCCGGCTGAGCCGATCTCCAGGTGACCCAGGA 180	QY 961 ATAANGAGAAACTCTGGCACCTGAGCTTGACCCAGAACTAGAAGAA 1020
Db 121 ATACCCCCGGCTGAGCCGATCTCCAGGTGACCCAGGA 180	Db 961 ATAANGAGAAACTCTGGCACCTGAGCTTGACCCAGAACTAGAAGAA 1020
QY 181 ACGGGACGGAGCTTCAGCCTGCAAAGAGTCTGAGTACCACTATGAGTAACGGCGGT 240	Db 961 AATAAGAGAAACTCTGGCACCTGAGCTTGACCCAGAACTAGAAGAA 1020
Db 181 ACGGGACGGAGCTTCAGCCTGCAAAGAGTCTGAGTACCACTATGAGTAACGGCGGT 240	Db 961 AATAAGAGAAACTCTGGCACCTGAGCTTGACCCAGAACTAGAAGAA 1020
QY 241 GAGACGAGGGTTCAGGTGGAGGTGGCCGATATACCGGGCTGTGCAACAGC 300	QY 781 CTCTATTGGAGAACCAACGCCCTTCAGTGGACCAAAAGTACCCAAACCTGCTGGTGGT 840
Db 241 GAGACGAGGGTTCAGGTGGAGGTGGCCGATATACCGGGCTGTGCAACAGC 300	Db 781 CTCTATTGGAGAACCAACGCCCTTCAGTGGACCAAAAGTACCCAAACCTGCTGGTGGT 840
QY 301 CTGCTGTACCCCTCAAGGGCACGGAGTCCTCTCCTGCAACGCCGGAGTTCTG 360	QY 841 AGAACATGGCCAACGGTGGCTACACTTCAGATGGCTCCCTGCAAACCTGCGGC 900
Db 301 CTGCTGTACCCCTCAAGGGCACGGAGTCCTCTCCTGCAACGCCGGAGTTCTG 360	Db 841 AGAACATGGCCAACGGTGGCTACACTTCAGATGGCTCCCTGCAAACCTGCGGC 900
QY 361 GATATGAAGGACCAAGTCAAGGATGCTGGAGGGCGTACTCCCTGGCACAGC 420	QY 901 ACSTPAGAGACAGCAGGGCTTCAGTTCTGCAAACACTTCTATGTTATATCA 960
Db 361 GATATGAAGGACCAAGTCAAGGATGCTGGAGGGCGTACTCCCTGGCACAGC 420	Db 901 ACGPATGCGACAGCAGGGCTTCAGTTCTGCAAACACTTCTATGTTATATCA 960
QY 421 ATTCGGTTGATGAGTGGATGCTGGATGCTGGCCATGGCTGGCACAGC 480	QY 961 ATAANGAGAAACTCTGGAGAACGGTCAAAGGTTCAGTGGCTCC 1020
Db 421 ATTCGGTTGATGAGTGGATGCTGGATGCTGGCCATGGCTGGCACAGC 480	Db 961 AATAANGAGAAACTCTGGAGAACGGTCAAAGGTTCAGTGGCTCC 1020
QY 481 GAGCTGGATGAACTGCTGCTGAGTGGCTACGGGAGACTGTACTTCAGTGGT 540	QY 1741 AGCAGGAAGTCACTGGCTCCCTACTGCGCTTCAAGGGCAACCTGCGGC 1800
Db 481 GAGCTGGATGAACTGCTGCTGAGTGGCTACGGGAGACTGTACTTCAGTGGT 540	Db 1741 AGCAGGAAGTCACTGGCTCCCTACTGCGCTTCAAGGGCAACCTGCGGC 1800
QY 541 CGGGGGGACTACATGCCCTCAACCGGAGGAATGCCACAGTGGTGGCTC 600	QY 1801 AATGGCGTGGCCCTCCACTGCGCTTCAAGGGCAACCTGCGGC 1860
Db 541 CGGGGGGACTACATGCCCTCAACCGGAGGAATGCCACAGTGGTGGCTC 600	Db 1801 AATGGCGTGGCCCTCCACTGCGCTTCAAGGGCAACCTGCGGC 1860
QY 601 AACCTGAAGCAATCCTGGCACCGTAACTTCAAGGAACTCAGGATCATC 660	QY 1861 TGACCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1920
Db 601 AACCTGAAGCAATCCTGGCACCGTAACTTCAAGGAACTCAGGATCATC 660	Db 1861 TGACCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1920
QY 661 TTGAGTTTCTGTTGAGATGCAAGTGGCTACGGGCAACTCAGTGGTGGATG 720	QY 1741 AGCAGGAAGTCACTGGCTCCCTACTGCGCTTCAAGGGCAACCTGCGGC 1800
Db 661 TTGAGTTTCTGTTGAGATGCAAGTGGCTACGGGCAACTCAGTGGTGGATG 720	Db 1741 AGCAGGAAGTCACTGGCTCCCTACTGCGCTTCAAGGGCAACCTGCGGC 1800
QY 721 AAAGACCAGAGAAAGGATGGGAATTCACAGTGTGGAGCTAAATCGAGGCAATAATGTC 780	QY 1801 AATGGCGTGGCCCTCCACTGCGCTTCAAGGGCAACCTGCGGC 1860
Db 721 AAAGACCAGAGAAAGGATGGGAATTCACAGTGTGGAGCTAAATCGAGGCAATAATGTC 780	Db 1801 AATGGCGTGGCCCTCCACTGCGCTTCAAGGGCAACCTGCGGC 1860

Db	1861	TGACCTCTGTCTGCTGTTACTATAGCCGAGATTAGGGACCTCATCTTACAGCAAGATACTCTC	1920	Db	2941	GCCATCATGGAAAGGGAGATGTAGGGACCTCATCTTACAGCAAGATACTCTC	3000
QY	1921	CCCCCTAACACANTCTGAAGGCCACCAGCCPATGGTGTCAGGCCCTGTGCCCTGT	1980	QY	3001	TGGAAATCATCAATCTTTACTCTCAAGAGACTCTGTGATGGACTCTGACTGAGCT	3060
Db	1921	CCCCCTAACACAACTCTGAAGGCCACCAGCCCTATGGTGTCAGGCCCTGTGCCCTGT	1980	Db	3001	TGGAAATCATCAATCTTTACTCTCAAGAGACTCTGTGATGGACTCTGAGCT	3060
QY	1981	GGTCAAGGGACCAAGAACACAATCCACACTCTGTGTCATAGTGTACCTCTCA	2040	QY	3061	TGAGACATCCTAGGGGCCAGACATGGACTCTGTGAGGGACTGCTGCTCACCTG	3120
Db	1981	GGTCAAGGGACCAAGAACACAATCCACACTCTGTGTCATAGTGTACCTCTCA	2040	Db	3061	TGAGACATCCTAGGGGCCAGACATGGACTCTGTGAGGGACTGCTGCTCACCTG	3120
QY	2041	CGCACACMCACCAACCCAGGACTTCACACTAACACTCTCGGTTGGCAAAACCGTCACT	2100	QY	3121	CCTCTCACCTGCATAGCACCTTGGCAAGGCCCTAAGCCTTGCAGGCTGCGGATTGGCCAGATCTGC	3180
Db	2041	CGAACACMCACCAACCCAGGACTTCACACTAACACTCTCGGTTGGCAAAACCGTCACT	2100	Db	3121	CCTCTCACCTGCATAGCACCTTGGCAAGGCCCTAAGCCTTGCAGGCTGCGGATTGGCCAGATCTGC	3180
QY	2101	CTGCTGGAGGCCAAGGCTACTCTCAAGGGTTGAAATACTTCATACCTTACCCCT	2160	QY	3181	AACACCAACTGCMGGAAATCTCUTCATGTTGCGCTTACAGANGTTGCAACCTCTC	3240
Db	2101	CTGCTGGAGGCCAAGGCTACTCTCAAGGGTTGAAATACTTCATACCTTACCCCT	2160	Db	3181	AACACCAACTGCMGGAAATCTCUTCATGTTGCGCTTACAGANGTTGCAACCTCTC	3240
QY	2161	AGTCCTGTGAGAACCCAGGTAGGAAAATGCTGTGAAAGCAACTGACTGACCTC	2220	QY	3241	TTTTATAGATGACCCAAACCCCTCTCTGCTTGCCTCAAACCTGCCAATATAACCA	3300
Db	2161	AGTCCTGTGAGAACCCAGGTAGGAAAATGCTGTGAAAGCAACTGACTGACCTC	2220	Db	3241	TTCCTTATAGATGACCCAAACCCCTCTCTGCTTGCCTCAAACCTGCCAATATAACCA	3300
QY	2221	CGGATCCCTGAGGGTGAATGGTCAAGGGCTTCTCCAAATCTGTGTGAAAGCAACTGACTGACCTC	2280	QY	3301	CACTTTGTTGAAATTAATAAAAAAA	3334
Db	2221	CGGATCCCTGAGGGTGAATGGTCAAGGGCTTCTCCAAATCTGTGTGAAAGCAACTGACTGACCTC	2280	Db	3301	CACTTTGTTGAAATTAATAAAAAAA	3334
QY	2281	GTCATCATCCCCCAGAGGTGACAGGGCTACAGGGGGTTCTCACAGCCCTGTCAAGC	2340				
Db	2281	GTCATCATCCCCCAGAGGTGACAGGGCTACAGGGGGTTCTCACAGCCCTGTCAAGC	2340				
QY	2341	CTTGTGTATGGACTTATGGGTGACAAGATAATGACRGTGGATGGAACTCTCCCA	2400				
Db	2341	CTTGTGTATGGACTTATGGGTGACAAGATAATGACRGTGGATGGAACTCTCCCA	2400				
QY	2401	GCTGAACTTTCCACCTGGAGTCTGGACTCTGGGAAATCGGACTGTCCTCTTATAGGTCC	2460				
Db	2401	GCTGAACTTTCCACCTGGAGTCTGGACTCTGGGAAATCGGACTGTCCTCTTATAGGTCC	2460				
QY	2461	AAATGATGTGACCCAGCTCTGCACTCTGGGAGATAACCACTCATGGCTCAGTGC	2520				
Db	2461	AAATGATGTGACCCAGCTCTGCACTCTGGGAGATAACCACTCATGGCTCAGTGC	2520				
QY	2521	CCACAGAAACTGTCCCTGGAGTTGGCTGCGGAGAAGTGTCAAGTGGACCTCT	2580				
Db	2521	CCACAGAAACTGTCCCTGGAGTTGGCTGCGGAGAAGTGTCAAGTGGACCTCT	2580				
QY	2581	GATGGGTGCAACTTCGCACTCTGGGAAAGTGTGGAGAAGTGGCACTCTGGCAGT	2640				
Db	2581	GATGGGTGCAACTTCGCACTCTGGGAAAGTGTGGAGAAGTGGCACTCTGGCAGT	2640				
QY	2641	GCTGACTACATGCTATCGTCAGCTGCTGCTGCTGGCTGGCTGGCTGGCTGCTG	2700				
Db	2641	GCTGACTACATGCTATCGTCAGCTGCTGCTGCTGGCTGGCTGGCTGGCTGCTG	2700				
QY	2701	TGGCGAGAACCCAAAGTATGGCTGGGATGGCTGGCTGGCTGGCTGGCTGGCTG	2760				
Db	2701	TGGCGAGAACCCAAAGTATGGCTGGGATGGCTGGCTGGCTGGCTGGCTGGCTG	2760				
QY	2761	TGAAACCACTAGATTCGGCTGAAAGTGGCACTCTGGGACCTGTACTCCATC	2820				
Db	2761	TGAAACCACTAGATTCGGCTGAAAGTGGCACTCTGGGACCTGTACTCCATC	2820				
QY	2821	CTGCTCACCGCTGTGACCTGCTACTCTGGAAAGAAATCAAACCTAGGATCACAGTC	2880				
Db	2821	CTGCTCACCGCTGTGACCTGCTACTCTGGAAAGAAATCAAACCTAGGATCACAGTC	2880				
QY	2881	TCCAAGGTGGATGATGATGCTGACTCTCAAGAACCTGTGACCTGAGCTGACAGCTG	2940				
Db	2881	TCCAAGGTGGATGATGATGCTGACTCTCAAGAACCTGTGACCTGAGCTGACAGCTG	2940				
QY	2941	GCCATCATGGAAAGGGAGGATGTAGGGACCACTCATCTTACAGCAAGAAATCACTC	3000				

AAB35333
ID AAB35333 standard; Protein; 1001 AA.

XX

AAB35333;

XX DT 08-MAY-2001 (first entry)

XX Human TR13 receptor protein SEQ ID NO: 40.

XX Human; tumour necrosis factor receptor; TR13; TR14; infection; cancer; autoimmune disease; allergy; inflammatory disease; graft rejection; apoptosis; cardiovascular disease; aneurysm.

XX Homo sapiens.

PN WO200105834-A1.

XX PD 25-JAN-2001.

XX PP 14-JUL-2000; 2000WO-US19343.

XX PR 16-JUL-1999; 99US-0144087.

PR 18-AUG-1999; 99US-0149450.

PR 20-AUG-1999; 99US-0149712.

PR 20-SEP-1999; 99US-0153089.

XX (HUMA-) HUMAN GENOME SCI INC.

XX PI Ruben SM, Ni J, Young PE;

XX WPI; 2001-112682/12.

XX Nucleic acids encoding 2 human tumor necrosis factor receptor polypeptides (TR13) and (TR14), useful for the prevention, diagnosis and treatment of, e.g. cancers, acquired immune deficiency syndrome and hypohidrotic ectodermal dysplasia.

PR Claim 40; Page 398-401; 418pp; English.

XX The present invention provides the protein and coding sequences of the human tumour necrosis factor receptors TR13 and TR14. These sequences are useful in the diagnosis and treatment of many diseases, including cancer, autoimmune diseases, cardiovascular disorders, allergies, aneurysms and neurodegenerative diseases, graft rejection, inflammation, aneurysms and infections.

XX Sequence 1001 AA;

SQ Query Match 100.0%; Score 1001; DB 22; Length 1001;

Best Local Similarity 100.0%; Pred. No. 0; Mismatches 0; Indels 0; Gaps 0;

Matches 1001; Conservative 0;

1 MAEPGHSIHLSLAIVRGRTERRIPRLWLLWAGTAFOVTTGTSPELLACKESYHYBTA 60

1 MAEPGHSIHLSLAIVRGRTERRIPRLWLLWAGTAFOVTTGTSPELLACKESYHYBTA 60

61 CDSTGCSRMRVVAVPPTPGLCTSLPPDVKGTCTECSFCNACGFMDKMDQSKPCAGRSIGT 120

61 CDSTGCSRMRVVAVPPTPGLCTSLPPDVKGTCTECSFCNACGFMDKMDQSKPCAGRSIGT 120

61 GIRFDEWDELPHGFAISLAMMELDSSAESTGCTTSKVRGTYIAFTDECTATMYA 180

61 GIRFDEWDELPHGFAISLAMMELDSSAESTGCTTSKVRGTYIAFTDECTATMYA 180

181 VNLKOSGTVNFEYTYPDSSIIFFVQNDQOCQNAADDSSRMKMTTEKGWFPHSVELNRRGN 240

181 VNLKOSGTVNFEYYPDSSIIFFVQNDQOCQNAADDSSRMKMTTEKGWFPHSVELNRRGN 240

241 VLYWRTTAFTSWTKVKPVLPVRLVNRNIAITGVAYTSECFCPKCERGTYADKGSSPKLCPANSY 300

241 VLYWRTTAFTSWTKVKPVLPVRLVNRNIAITGVAYTSECFCPKCERGTYADKGSSPKLCPANSY 300

301 SNKGTSCHOCDPDKYSEKGSSCNVRPACTDKDYFTHTACDANGETQLMYKWAQPKIC 360

301 SNKGTSCHOCDPDKYSEKGSSCNVRPACTDKDYFTHTACDANGETQLMYKWAQPKIC 360

Qy	361 SEDLEGAVKLPA5GVKTHCPPNPNGFPXTNNSTCOPCPGYSNSGSDCTRCPAGTEAVG 420	Db	361 SEDLEGAVKLPA5GVKTHCPPNPNGFPXTNNSTCOPCPGYSNSGSDCTRCPAGTEAVG 420
Qy	421 FEYKWNNTLPTNMETTTLVSGINFEYKMTGWEYAGDHLYTAAAGASDNDFMILTLVVGFR 480	Db	421 FEYKWNNTLPTNMETTTLVSGINFEYKMTGWEYAGDHLYTAAAGASDNDFMILTLVVGFR 480
Qy	481 PPQSVMDAENKEVARITPVEETLCSUNCLXPMVGNSRNTPVEWTGSKGKOSTTYI 540	Db	481 PPQSVMDAENKEVARITPVEETLCSUNCLXPMVGNSRNTPVEWTGSKGKOSTTYI 540
Qy	541 IERNTTTSPTWAQRTFHAEASKYTNDAVAKYSINTNVANGYASVCRPCALAESDVG 600	Db	541 IERNTTTSPTWAQRTFHAEASKYTNDAVAKYSINTNVANGYASVCRPCALAESDVG 600
Qy	601 SCTSCPAGYIDRDSGTCSCPPNTLKAHQPTVQACVPCGPCTKNNKTHSLCYNDCTF 660	Db	601 SCTSCPAGYIDRDSGTCSCPPNTLKAHQPTVQACVPCGPCTKNNKTHSLCYNDCTF 660
Qy	661 SRATPTRTFNNMFSALANTVTLAGPSFTNSKGKLYKPFHFTLSSLGNOGRKMSVCTDNTDF 720	Db	661 SRATPTRTFNNMFSALANTVTLAGPSFTNSKGKLYKPFHFTLSSLGNOGRKMSVCTDNTDF 720
Qy	721 LRIPEGESFSKSSTAYVCOAVIIPPEVYKACVSQPLSADRLLGTVTDMLDGTTS 780	Db	721 LRIPEGESFSKSSTAYVCOAVIIPPEVYKACVSQPLSADRLLGTVTDMLDGTTS 780
Qy	781 PAELPHLBSLGLIPDVTYRSPQKTVPSLIPDTCSGDT 840	Db	781 PAELPHLBSLGLIPDVTYRSPQKTVPSLIPDTCSGDT 840
Qy	841 CDGCNFPHLWESAAACPLCSVADYTHAIVSSCVAGQKITYVWRPLCGSGGISLSPQRVT 900	Db	841 CDGCNFPHLWESAAACPLCSVADYTHAIVSSCVAGQKITYVWRPLCGSGGISLSPQRVT 900
Qy	901 ICKTIDFWLKVGISAGTCALLTATTCYFWKQKQLEKTYSKLVMAATLKDQDLPADS 960	Db	901 ICKTIDFWLKVGISAGTCALLTATTCYFWKQKQLEKTYSKLVMAATLKDQDLPADS 960
Qy	961 CAIMEGEDVEDDLIFTSKNSLGRSNHLPBRGLIMDLTQCR 1001	Db	961 CAIMEGEDVEDDLIFTSKNSLGRSNHLPBRGLIMDLTQCR 1001